Distinguished in Cerebellar Degeneration

Dimitri Psimaras

Paris, FR 
Distinguished in Cerebellar Degeneration
Paris, FR 
OverviewLocationsClinical Research

Overview

Dimitri Psimaras practices in Paris, France. Mr. Psimaras is rated as a Distinguished expert by MediFind in the treatment of Cerebellar Degeneration. His top areas of expertise are Encephalitis, Paraneoplastic Cerebellar Degeneration, Cerebellar Degeneration, and Anti-NMDA Receptor Encephalitis.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Cerebellar Degeneration.

Gender
Male

Locations

Paris, France
Other Locations
Lyon, France
Bron, France
Foix, France
Université Paris Est, INSERM U955, Et Fondation FondaMental, Creteil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies
Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies
Enrollment Status: Completed
Publish Date: February 10, 2023
Intervention Type: Other
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Enrollment Status: Terminated
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

165 Total Publications

Immune Checkpoint Inhibitors Trigger and Exacerbate Anti-CV2/CRMP5 Paraneoplastic Neurologic Syndromes.
Immune Checkpoint Inhibitors Trigger and Exacerbate Anti-CV2/CRMP5 Paraneoplastic Neurologic Syndromes.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Psimaras's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile